Clinical Trial News
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Get news By email or subscribe to our News feeds.
Posted Yesterday in Clinical Trials
Data Supports Advancement of Product Development
CONCORD, Calif.--(BUSINESS WIRE)--Feb 9, 2010 - Cerus
Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of
red blood cells treated with the INTERCEPT Blood System met its
primary endpoint, with preliminary analysis demonstrating that
greater than 75 percent of treated cells continued to circulate 24
hours following...
Read more... Posted Yesterday in Clinical Trials
Denosumab Trial Met Primary and All Secondary Endpoints by
Significantly Delaying Time to First Skeletal Related Event and
Significantly Reducing First-and-Subsequent Skeletal Related Events
Compared to Zometa Second Phase 3 Advanced Cancer Trial to
Demonstrate Denosumab Superiority Versus Zometa
THOUSAND OAKS, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Amgen
(NASDAQ: AMGN) today
announced that a...
Read more... Posted Yesterday in Clinical Trials
- Paper Examines the Potential of Microplasmin to Improve the
Treatment of a Range of Back of the Eye Diseases
LEUVEN, Belgium, February 9/PRNewswire-FirstCall/ --
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical
company focused on the discovery and development of innovative
treatments for eye disease, vascular disease and cancer, announces
today that the positive microplasmin Phase...
Read more... Posted 2 Days Ago in Clinical Trials
~ Conference call will be held today at 4:45 p.m. Eastern
time ~
LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 5, 2010 - AMAG
Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company
focused on the development and commercialization of a therapeutic
iron compound to treat anemia and novel imaging agents to aid in
the diagnosis of cancer and cardiovascular disease, today provided
a safety...
Read more... Posted 2 Days Ago in Clinical Trials
Tβ4 – Potential New Therapeutic Agent for
Liver Failure
BETHESDA, Md.--(BUSINESS WIRE)--Feb 8, 2010 - REGENERX
BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that
researchers have correlated Tβ4 levels with the
clinical course of patients with hepatitis B virus-related liver
failure. It was reported that serum thymosin β4 levels
were...
Read more... Posted 2 Days Ago in Clinical Trials
Data show significant Neuraminidase Inhibition Antibody
Titers in VLP vaccine recipients
ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ -- Novavax, Inc.
(NASDAQ: NVAX) announced
today new data from a clinical study that began in May of 2009
among healthy adults 18 to 49 years of age with Novavax's trivalent
seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine
matched the...
Read more... Posted 2 Days Ago in Clinical Trials
Geneva, Switzerland, 8 February 2010 - Addex
Pharmaceuticals (SIX:ADXN), the allosteric
modulation company, announced today that ADX71943 has demonstrated
statistically significant analgesic-like effects in three
preclinical models of pain.
In the first model, ADX71943 reversed complete Freund adjuvant
(CFA)-induced reductions in withdrawal thresholds in a dose-related
manner, with a...
Read more... Posted 2 Days Ago in Clinical Trials
SHELTON, Conn., Feb. 8 /PRNewswire/ -- Cara Therapeutics, Inc.
today announced positive data in a Phase II proof-of-concept
clinical trial of its peripherally-restricted kappa opioid agonist,
CR845. The 46 patient Phase II, multi-center, double-blind,
placebo-controlled study was conducted at eight hospitals in the
United States and evaluated the efficacy and safety of CR845 in
women...
Read more... Posted 2 Days Ago in Clinical Trials
- Results presented at hematologic malignancies conference in
Singapore -
- STA-9090 inhibits WT1, a key driver of leukemias -
- STA-9090 currently being studied in two AML clinical trials
-
LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 8, 2010 -
Synta Pharmaceuticals Corp. (NASDAQ:
SNTA) today announced that preclinical results presented at the
“Bridging the Gap 2010” Hematologic...
Read more... Posted 2 Days Ago in Clinical Trials
Increased antigen-specific T-cell and antibody responses
shown in second, higher dose group
SAN DIEGO--(BUSINESS WIRE)--Feb 8, 2010 - Inovio Biomedical
Corporation (NYSE Amex: INO), a leader in DNA vaccine design,
development and delivery, announced today additional interim safety
and immunogenicity data from its therapeutic cervical cancer
vaccine (VGX-3100) trial. VGX-3100 is a DNA...
Read more... Posted 2 Days Ago in Clinical Trials
Increased antigen-specific T-cell and antibody responses shown
in second, higher dose group
SAN DIEGO, CA February 8, 2010 -- Inovio Biomedical Corporation
(NYSE Amex: INO), a leader in DNA vaccine design, development and
delivery, announced today additional interim safety and
immunogenicity data from its therapeutic cervical cancer vaccine
(VGX-3100) trial. VGX-3100 is a DNA vaccine...
Read more... Posted 5 Days Ago in Clinical Trials
BALLERUP, Denmark, Feb. 1 /PRNewswire-USNewswire/ -- LEO Pharma
today announced that in a Phase III study, PEP005 (ingenol
mebutate) Gel, the company's lead candidate for the topical
treatment of actinic (solar) keratosis (AK) or pre-cancerous
lesions, met its primary clinical endpoint of complete clearance of
AK lesions in non-head locations. Findings from the REGION Ib study
in body AK...
Read more... Posted 5 Days Ago in Clinical Trials
Data sponsored by the Canadian Fabry Disease Initiative
(CFDI) to be presented by Dr. Michael West, Dalhousie
University
CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Shire plc ,
the global specialty biopharmaceutical company, today announced
that data from one of three Phase III clinical trials for
velaglucerase alfa, the company's enzyme replacement therapy (ERT)
in development for...
Read more... Posted 5 Days Ago in Clinical Trials
INDIANAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- In a new study,
60 mg of Cymbalta® (duloxetine HCl) taken once daily
significantly reduced chronic low back pain, as measured by the
Brief Pain Inventory (BPI) average pain rating, compared with
placebo.(1) The data were presented today at the annual meeting of
the American Academy of Pain Medicine (AAPM) in San Antonio,
Texas.
A total of...
Read more... Posted 5 Days Ago in Clinical Trials
CARMIEL, Israel, Feb. 4 /PRNewswire-FirstCall/ -- Protalix
Biotherapeutics, Inc. (NYSE- Amex: PLX) today announced that data
from its pivotal Phase III trial of taliglucerase alfa in patients
with Gaucher disease will be presented at the Annual Meeting of the
Lysosomal Disease Network: WORLD Symposium 2010, February 10-12,
2010 in Miami, Florida.
Hanna Rosenbaum, M.D., Director of...
Read more... Posted 5 Days Ago in Clinical Trials
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Tanezumab, a
humanized monoclonal antibody that targets nerve-growth factor,
reduced pain in three common pain conditions, according to the
results from three phase two studies presented today in a single
poster at the American Academy of Pain Medicine's 26th Annual
Meeting.
Researchers from Pfizer presented the results from three
separate...
Read more... Posted 5 Days Ago in Clinical Trials
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Findings from a
retrospective analysis of a three-week treatment program for
chronic pain revealed African Americans experienced worse outcomes
compared to a matched group of Caucasians. The research was
presented today at the American Academy of Pain Medicine's 26th
Annual Meeting in San Antonio.
"Our research showed important differences in...
Read more... Posted 5 Days Ago in Clinical Trials
Data CONFIRMS safe and effective use of CREON® in pediATRIC
PAtients -
MARIETTA, Ga., Feb. 5 /PRNewswire-FirstCall/ -- Solvay
Pharmaceuticals, Inc. announced today that Phase IIIb data
published in the January issue of Clinical Therapeutics confirm
that CREON® (pancrelipase) Delayed-Release Capsules
significantly improves a key measure of fat absorption in children
aged 7-11 years who...
Read more... Posted 5 Days Ago in Clinical Trials
Pooled Observations Show Low Rate of
Immunogenicity
SEATTLE--(BUSINESS WIRE)--Feb 2, 2010 - ZymoGenetics, Inc.
(NASDAQ:ZGEN), today announced the publication of pooled safety and
immunogenicity observations from eight clinical trials of RECOTHROM
in the February issue of the Journal of the American College of
Surgeons. The authors concluded that RECOTHROM is a
well-tolerated topical...
Read more... Posted 5 Days Ago in Clinical Trials
Phase III Trial Expected to Start by Q4 2010 or Q1 2011
Conference Call and Webcast to Be Held Today at 5:00 p.m.
ET
NOVATO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- BioMarin
Pharmaceutical Inc. (NASDAQ:BMRN) today
announced an update on the Phase I/II trial for BMN 110 or
N-acetylgalactosamine 6-sulfatase (GALNS), intended for the
treatment of the lysosomal storage disorder...
Read more...
